Discover and read the best of Twitter Threads about #nevertoolate
Most recents (4)
Here we go then. For the 134th time, I welcome you to the daily thread covering all the news and developments from #Russia's war of choice and invasion of its peaceful neighbour #Ukraine.
Updated in real time throughout the day, read on!
#StandWithUkraine
Updated in real time throughout the day, read on!
#StandWithUkraine
The British intelligence update today is interesting.
#Russia continues "mobilisation by stealth" as detailed here.
In some regions quotas are given and residents are strongly urged to "volunteer"
#SaveUkraine
#Russia continues "mobilisation by stealth" as detailed here.
In some regions quotas are given and residents are strongly urged to "volunteer"
#SaveUkraine
When I was in middle school I wanted to be an astronaut, but was told women couldn’t be astronauts. #SallyRide was older than me but she didn’t let that stop her.
It stopped me.
2/7
It stopped me.
2/7
In HS I was the top student in every #math class I took til precalc. Didn't it was ok to have to work at being good at math. No adult recognized my potential and pushed me. I lost interest in spite of my math SAT score being higher than my verbal.
#Fear #PerfectionProblems
3/7
#Fear #PerfectionProblems
3/7
#WeeklyCardioReview AUGUSTUS trial #NeverTooLate #Apixaban in patients requiring DAPT. Two key aspects to discuss here: 1) Should Apixaban 5mg/BID be the only NOAC used with triple therapy? 2) Time to move to NOAC+Clopidogrel dual therapy? enjoy thread and comment! 😉
Summary: AUGUSTUS RCT 4,614 ppl requiring DAPT (ACS and-or PCI) factorial design: Apixa vs Warfarin (NOAC research question), and ASA vs placebo (triple vs dual tx question) for 6 months. Study powered for bleeding outcomes and had guts to assume no interaction, stay tuned
Major or clinically relevant nonmajor bleeding lower in Apixa vs Warfarin HR 0.69 (0.58-0.81; superiority P<0.001), ASA vs placebo 1.89 (1.59-2.24; placebo superiority P<0.001). Apixa Vs Warfa, and ASA vs placebo similar incidence of ischemic events
#WeeklyCardioReview PARTNER 3 and Evolut Low Risk TAVR #NeverTooLate. Includes a home-made meta-analysis at the end. Time to re-think the standard for treating AS?
PARTER 3: 1000 pts, mean STS 1.9%, death/stroke/rehosp 1 year lower in TAVR HR 0.54; 95% CI, 0.37 to 0.79; P=0.001. At 30 days lower rate of stroke P=0.02 and death or stroke P=0.01 and new AF P<0.001.
@NEJM nejm.org/doi/10.1056/NE… @tavrkapadia @djc795 @J_M_McCabe @EdwardsLifesci
@NEJM nejm.org/doi/10.1056/NE… @tavrkapadia @djc795 @J_M_McCabe @EdwardsLifesci
shorter index hospitalization and lower risk of a poor treatment outcome (death or a low KCCQ score at 30 days (P<0.001). No significant between-group differences in major vascular complications, new permanent pacemaker insertions, or moderate/severe paravalvular regurgitation.
